Tags

Type your tag names separated by a space and hit enter

Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection.
Dig Dis Sci 2012; 57(2):381-9DD

Abstract

BACKGROUND

Effector CD4+ helper T cells have historically been classified into T helper 1 (Th1) and Th2 based on the production of signature cytokines. The recently identified interleukin (IL)-17 cytokine family plays important roles in host immunity against intracellular pathogens and in chronic inflammatory conditions; data have implicated IL-17 in autoimmune and viral liver disease.

METHODS

This study used three patient groups with HCV infection: acute HCV who either cleared spontaneously or became chronically infected (n = 12), endstage liver disease from whom both peripheral and intrahepatic lymphocytes were studied directly ex vivo (n = 11), and 134 patients with different stages of HCV-related fibrosis from whom serum was collected concurrently with liver biopsy. Normal healthy subjects (n = 41) served as controls.

RESULTS

Acute HCV was not associated with expansion of either CD4+ or CD8+ T cells producing IL-17 (Th17, Tc17) or IL-22, and frequencies did not differ in the blood of patients who cleared versus became persistently infected. The hepatic compartment of chronic HCV patients demonstrated statistically more CD4+ and CD8+ that produced IL-17, IL-22 or both as compared to peripheral blood. These T cells displayed a distinct phenotypic profile, high expression of the homing receptor CD161 and low levels of inhibitory receptors, mucin-domain-containing-molecule-3 (Tim-3) and programmed-death 1. Using a sensitive ELISA, we found no significant differences in serum levels of IL-17 according to HCV-related fibrosis.

CONCLUSIONS

In chronic HCV, T cells producing IL-17/IL-22 may home to the liver; however, circulating levels of IL-17 do not correlate with fibrosis.

Authors+Show Affiliations

Division of Gastroenterology and Hepatology, Hepatitis C Center, Department of Medicine, University of Colorado Denver and National Jewish Hospital, Aurora, CO 80045, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

22183819

Citation

Foster, Richard G., et al. "Interleukin (IL)-17/IL-22-producing T Cells Enriched Within the Liver of Patients With Chronic Hepatitis C Viral (HCV) Infection." Digestive Diseases and Sciences, vol. 57, no. 2, 2012, pp. 381-9.
Foster RG, Golden-Mason L, Rutebemberwa A, et al. Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. Dig Dis Sci. 2012;57(2):381-9.
Foster, R. G., Golden-Mason, L., Rutebemberwa, A., & Rosen, H. R. (2012). Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. Digestive Diseases and Sciences, 57(2), pp. 381-9. doi:10.1007/s10620-011-1997-z.
Foster RG, et al. Interleukin (IL)-17/IL-22-producing T Cells Enriched Within the Liver of Patients With Chronic Hepatitis C Viral (HCV) Infection. Dig Dis Sci. 2012;57(2):381-9. PubMed PMID: 22183819.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. AU - Foster,Richard G, AU - Golden-Mason,Lucy, AU - Rutebemberwa,Alleluiah, AU - Rosen,Hugo R, Y1 - 2011/12/20/ PY - 2011/08/05/received PY - 2011/11/22/accepted PY - 2011/12/21/entrez PY - 2011/12/21/pubmed PY - 2012/4/13/medline SP - 381 EP - 9 JF - Digestive diseases and sciences JO - Dig. Dis. Sci. VL - 57 IS - 2 N2 - BACKGROUND: Effector CD4+ helper T cells have historically been classified into T helper 1 (Th1) and Th2 based on the production of signature cytokines. The recently identified interleukin (IL)-17 cytokine family plays important roles in host immunity against intracellular pathogens and in chronic inflammatory conditions; data have implicated IL-17 in autoimmune and viral liver disease. METHODS: This study used three patient groups with HCV infection: acute HCV who either cleared spontaneously or became chronically infected (n = 12), endstage liver disease from whom both peripheral and intrahepatic lymphocytes were studied directly ex vivo (n = 11), and 134 patients with different stages of HCV-related fibrosis from whom serum was collected concurrently with liver biopsy. Normal healthy subjects (n = 41) served as controls. RESULTS: Acute HCV was not associated with expansion of either CD4+ or CD8+ T cells producing IL-17 (Th17, Tc17) or IL-22, and frequencies did not differ in the blood of patients who cleared versus became persistently infected. The hepatic compartment of chronic HCV patients demonstrated statistically more CD4+ and CD8+ that produced IL-17, IL-22 or both as compared to peripheral blood. These T cells displayed a distinct phenotypic profile, high expression of the homing receptor CD161 and low levels of inhibitory receptors, mucin-domain-containing-molecule-3 (Tim-3) and programmed-death 1. Using a sensitive ELISA, we found no significant differences in serum levels of IL-17 according to HCV-related fibrosis. CONCLUSIONS: In chronic HCV, T cells producing IL-17/IL-22 may home to the liver; however, circulating levels of IL-17 do not correlate with fibrosis. SN - 1573-2568 UR - https://www.unboundmedicine.com/medline/citation/22183819/Interleukin__IL__17/IL_22_producing_T_cells_enriched_within_the_liver_of_patients_with_chronic_hepatitis_C_viral__HCV__infection_ L2 - https://doi.org/10.1007/s10620-011-1997-z DB - PRIME DP - Unbound Medicine ER -